Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PHISO-SCRUB is a topical small-molecule sponge formulation approved in 1977 for dermatological use. The specific indication and mechanism of action are not publicly detailed in available data, limiting visibility into its therapeutic positioning.
Product approaching loss of exclusivity with low competitive pressure (30/100), suggesting a mature, legacy asset with declining team investment and limited expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings and approaching LOE indicate minimal hiring and career advancement on this product. Roles available are primarily defensive commercial and managed markets positions focused on market share retention rather than growth.
Worked on PHISO-SCRUB at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.